Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper Post navigationPreviousPrevious post:Anavex to Present at Sigma-1 Receptors SymposiumNextNext post:Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory BoardRelated PostsAnavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 ConferenceNovember 6, 2020Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 ConferenceNovember 6, 2020
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020